Journal article
Use of anti‐CD20 antibody in the treatment of post‐transplant glomerulonephritis
Abstract
Post-transplant glomerulonephritis (PTGN) accounts for 4-10% of late graft loss. Six consecutive patients who developed PTGN 3-72 months post-transplant presented to our center with deteriorating kidney function and proteinuria. Three had focal segmental glomerulosclerosis; one had membranoproliferative glomerulonephritis Type 1; one recurrent membranous nephropathy; and one recurrent immunoglobin A nephropathy. All six were treated with an …
Authors
Damodar A; Mustafa R; Bhatnagar J; Panesar M; Gundroo A; Zachariah M; Blessios G; Tornatore K; Weber‐Shrikant E; Venuto R
Journal
Clinical Transplantation, Vol. 25, No. 3, pp. 375–379
Publisher
Wiley
Publication Date
5 2011
DOI
10.1111/j.1399-0012.2010.01245.x
ISSN
0902-0063
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antibodies, Anti-IdiotypicAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Follow-Up StudiesGlomerular Filtration RateGlomerulonephritisHumansImmunologic FactorsKidney Failure, ChronicKidney Function TestsKidney TransplantationMaleMiddle AgedPlasmapheresisPostoperative ComplicationsPrognosisProteinuriaRisk FactorsRituximabSurvival Rate